STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding
PHOTO ILLUSTRATION: STAT, PHOTO: HANDOUT
Hung is best known for founding Medivation — which developed Xtandi, a drug for prostate cancer — and then selling the company to Pfizer for $14 billion.
.png)
No hay comentarios:
Publicar un comentario